Oncternal Therapeutics Statistics
Share Statistics
Oncternal Therapeutics has 2.96M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 2.96M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 14.22% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,650 |
| FTD / Avg. Volume | 2.65% |
Short Selling Information
The latest short interest is 138.62K, so 4.68% of the outstanding
shares have been sold short.
| Short Interest | 138.62K |
| Short % of Shares Out | 4.68% |
| Short % of Float | 4.86% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.8 and the forward
PE ratio is null.
Oncternal Therapeutics's PEG ratio is
0.04.
| PE Ratio | -0.8 |
| Forward PE | n/a |
| PS Ratio | 40.15 |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncternal Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.94,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.94 |
| Quick Ratio | 6.94 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $29,074.07 |
| Profits Per Employee | $-1,462,185.19 |
| Employee Count | 27 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -93.8% in the
last 52 weeks. The beta is 1.36, so Oncternal Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | -93.8% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 4.96 |
| Relative Strength Index (RSI) | 25.25 |
| Average Volume (20 Days) | 62,268 |
Income Statement
In the last 12 months, Oncternal Therapeutics had revenue of 785K
and earned -39.48M
in profits. Earnings per share was -13.43.
| Revenue | 785K |
| Gross Profit | -28.97M |
| Operating Income | -41.71M |
| Net Income | -39.48M |
| EBITDA | 2.23M |
| EBIT | -39.48M |
| Earnings Per Share (EPS) | -13.43 |
Full Income StatementBalance Sheet
The company has 6.7M in cash and 318K in
debt, giving a net cash position of 6.38M.
| Cash & Cash Equivalents | 6.7M |
| Total Debt | 318K |
| Net Cash | 6.38M |
| Retained Earnings | -197.78M |
| Total Assets | 15.6M |
| Working Capital | 8.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -32.16M
and capital expenditures 0, giving a free cash flow of -32.16M.
| Operating Cash Flow | -32.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | -32.16M |
| FCF Per Share | -10.94 |
Full Cash Flow StatementMargins
Gross margin is -3690.19%, with operating and profit margins of -5313.89% and -5029.17%.
| Gross Margin | -3690.19% |
| Operating Margin | -5313.89% |
| Pretax Margin | -5029.17% |
| Profit Margin | -5029.17% |
| EBITDA Margin | 284.71% |
| EBIT Margin | -5313.89% |
| FCF Margin | -4097.32% |
